RedC Biotech

Company Overview

Snapshot

Founded in April 2015 by Ari Gargir, RedC Biotech operates with 1–10 employees. The company has raised $3M across four funding rounds from one investor, focusing on developing universal red blood cells from stem cells. In March 2022, RedC Biotech secured a grant, highlighting its progress in the biotechnology sector.

Business overview

RedC Biotech is a preclinical development-stage company focused on creating universal red blood cells from stem cells using a patented cultivation technology. This highly scalable process aims to meet the global demand for safe red blood cell transfusions, providing a blood type suitable for almost any patient with potency comparable to current transfusion methods. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, with applications in biomaterials and tissue engineering, serving healthcare providers and hospitals globally.

Strategic signal

RedC Biotech is poised to revolutionize blood transfusions by developing lab-grown universal red blood cells from stem cells, as highlighted in news from September 2025 and December 2024. This initiative addresses critical global shortages and the need for universal compatibility, signaling a significant advancement in biotechnology and potentially reducing reliance on traditional blood donations. For investors, this indicates a strong potential for market disruption and a solution to a widespread healthcare challenge.

Company Intelligence Q&A

What is RedC Biotech's core mission?

RedC Biotech's core mission is to develop universal red blood cells from stem cells using patented cultivation technology, aiming to provide life-saving transfusions and advanced therapies globally.

When was RedC Biotech founded and by whom?

RedC Biotech was founded in April 2015 by Ari Gargir.

What significant recognition did RedC Biotech receive in March 2022?

In March 2022, Ari Gargir from RedC Biotech won the Ziv Aviram Foundation competition in Dubai.

What is RedC Biotech's approach to addressing blood shortages?

RedC Biotech is developing a process to create universal red blood cells in the lab from stem cells, aiming to alleviate shortages and replace the need for traditional blood donors, as reported in June 2022.

What was a key achievement for RedC Biotech in April 2020?

In April 2020, RedC Biotech was recognized as the winner of the Startup of Israel competition.